Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) have received an average recommendation of "Hold" from the twelve research firms that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $5.2188.
Several equities analysts have recently commented on MRVI shares. Royal Bank Of Canada dropped their target price on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating for the company in a research report on Tuesday, August 12th. Weiss Ratings reissued a "sell (e+)" rating on shares of Maravai LifeSciences in a research note on Saturday, September 27th.
Check Out Our Latest Report on Maravai LifeSciences
Hedge Funds Weigh In On Maravai LifeSciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Callan Family Office LLC bought a new position in Maravai LifeSciences in the 2nd quarter valued at approximately $25,000. Ethic Inc. acquired a new position in Maravai LifeSciences in the 2nd quarter valued at approximately $26,000. McAdam LLC acquired a new position in Maravai LifeSciences in the 1st quarter valued at approximately $31,000. EntryPoint Capital LLC acquired a new position in Maravai LifeSciences in the 1st quarter valued at approximately $32,000. Finally, Prudential Financial Inc. acquired a new position in Maravai LifeSciences in the 2nd quarter valued at approximately $36,000. Institutional investors own 50.25% of the company's stock.
Maravai LifeSciences Price Performance
Shares of NASDAQ:MRVI opened at $3.19 on Monday. The firm has a 50 day moving average of $2.64 and a 200-day moving average of $2.37. The stock has a market capitalization of $814.60 million, a PE ratio of -2.35 and a beta of 0.33. The company has a current ratio of 5.16, a quick ratio of 4.49 and a debt-to-equity ratio of 0.68. Maravai LifeSciences has a 12 month low of $1.66 and a 12 month high of $8.53.
About Maravai LifeSciences
(
Get Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Maravai LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.
While Maravai LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
